These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 37326719)
1. Platycodin D represses β-catenin to suppress metastasis of cetuximab-treated KRAS wild-type colorectal cancer cells. Lv Y; Wang W; Liu Y; Yi B; Chu T; Feng Z; Liu J; Wan X; Wang Y Clin Exp Metastasis; 2023 Aug; 40(4):339-356. PubMed ID: 37326719 [TBL] [Abstract][Full Text] [Related]
2. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways. Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734 [TBL] [Abstract][Full Text] [Related]
3. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis. Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137 [TBL] [Abstract][Full Text] [Related]
4. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938 [TBL] [Abstract][Full Text] [Related]
5. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771 [No Abstract] [Full Text] [Related]
6. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab. Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318 [TBL] [Abstract][Full Text] [Related]
7. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations. Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236 [TBL] [Abstract][Full Text] [Related]
8. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc. Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133 [TBL] [Abstract][Full Text] [Related]
9. Honokiol enhances the sensitivity of cetuximab in KRAS Zhu Q; Zhang R; Gu X; Zhao Z; Gao Q; Chen M; Wu Q; Xie T; Sui X Theranostics; 2024; 14(14):5443-5460. PubMed ID: 39310106 [No Abstract] [Full Text] [Related]
10. Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expression. Zhang X; Zhou W; Wu C; Jiang J; Guo Q; Feng L; Cheng X; Zhang X Sci Rep; 2024 May; 14(1):10642. PubMed ID: 38724565 [TBL] [Abstract][Full Text] [Related]
11. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D, a natural compound found in Platycodon grandiflorum. Lee H; Bae S; Kim YS; Yoon Y Life Sci; 2011 Sep; 89(11-12):388-94. PubMed ID: 21798269 [TBL] [Abstract][Full Text] [Related]
12. Raddeanin A inhibits growth and induces apoptosis in human colorectal cancer through downregulating the Wnt/β-catenin and NF-κB signaling pathway. Wang Y; Bao X; Zhao A; Zhang J; Zhang M; Zhang Q; Ma B Life Sci; 2018 Aug; 207():532-549. PubMed ID: 29972765 [TBL] [Abstract][Full Text] [Related]
13. Histone Demethylase JMJD2D Interacts With β-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice. Peng K; Kou L; Yu L; Bai C; Li M; Mo P; Li W; Yu C Gastroenterology; 2019 Mar; 156(4):1112-1126. PubMed ID: 30472235 [TBL] [Abstract][Full Text] [Related]
14. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways. Chun J; Kim YS Chem Biol Interact; 2013 Oct; 205(3):212-21. PubMed ID: 23867902 [TBL] [Abstract][Full Text] [Related]
15. Platycodin D sensitizes Liu Y; Tian S; Yi B; Feng Z; Chu T; Liu J; Zhang C; Zhang S; Wang Y Front Oncol; 2022; 12():1046143. PubMed ID: 36387129 [TBL] [Abstract][Full Text] [Related]
16. Sanguisorba officinalis L. suppresses 5-fluorouracil-sensitive and-resistant colorectal cancer growth and metastasis via inhibition of the Wnt/β-catenin pathway. Zhang W; Peng C; Yan J; Chen P; Jiang C; Sang S; Yuan Y; Hong Y; Yao M Phytomedicine; 2022 Jan; 94():153844. PubMed ID: 34785413 [TBL] [Abstract][Full Text] [Related]
17. Platycodin D, a triterpenoid saponin from Platycodon grandiflorum, suppresses the growth and invasion of human oral squamous cell carcinoma cells via the NF-κB pathway. Zhang Z; Zhao M; Zheng W; Liu Y J Biochem Mol Toxicol; 2017 Sep; 31(9):. PubMed ID: 28548219 [TBL] [Abstract][Full Text] [Related]
18. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR. Du F; Qiao C; Li X; Chen Z; Liu H; Wu S; Hu S; Qiu Z; Qian M; Tian D; Wu K; Fan D; Nie Y; Xia L Theranostics; 2019; 9(13):3879-3902. PubMed ID: 31281520 [No Abstract] [Full Text] [Related]
19. Platycodin D induces apoptosis and triggers ERK- and JNK-mediated autophagy in human hepatocellular carcinoma BEL-7402 cells. Li T; Xu XH; Tang ZH; Wang YF; Leung CH; Ma DL; Chen XP; Wang YT; Chen Y; Lu JJ Acta Pharmacol Sin; 2015 Dec; 36(12):1503-13. PubMed ID: 26592509 [TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data. Guo GF; Wang YX; Zhang YJ; Chen XX; Lu JB; Wang HH; Jiang C; Qiu HQ; Xia LP World J Gastroenterol; 2019 Apr; 25(15):1840-1853. PubMed ID: 31057298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]